Basic/Clinical Science Session
Cellular Therapies for Autoimmune Kidney Diseases
October 23, 2026 | 02:00 PM - 04:00 PM
Location: Mile High Ballroom 1A, Convention Center
Session Description
Cellular therapies are rapidly reshaping the treatment landscape for autoimmune kidney diseases. This session explores emerging data on chimeric antigen receptor T-cell therapy (CAR-T), bispecific T-cell engagers, and related immune-reprogramming strategies; highlights mechanisms, early clinical experience, and safety considerations; and discusses the potential for durable, treatment-free remission in severe glomerular diseases.
Learning Objective(s)
- Describe the mechanisms of action and key biological differences between CAR-T cells, bispecific T-cell engagers, and other immune-redirecting cellular therapies in autoimmune kidney diseases
- Evaluate emerging clinical trial data on the efficacy and safety of CAR-T and bispecific T-cell engager therapies in autoimmune and immune-mediated glomerular diseases, including risks of cytokine-release syndrome, immune effector cell-associated neurotoxicity syndrome, and infectious complications
- Discuss principles of patient selection, toxicity mitigation, and multidisciplinary care to identify where immune-redirecting therapies may fit within current and future treatment algorithms for refractory autoimmune kidney diseases
Learning Pathway(s)
- Glomerular Diseases
- Pharmacology
Moderators
Presentations
- CAR-T Cells and Bispecific T-Cell Engagers in Autoimmune Diseases
02:00 PM - 02:40 PM
- Early Results from CAR-T Trials in Lupus Nephritis
02:40 PM - 03:20 PM
- Challenges, Successes, and Learning in Setting Up CAR-T Trials for Kidney Diseases
03:20 PM - 04:00 PM